BACKGROUND: The aim of this study was to define the clinical behavior and prognostic indicators of outcome in Hürthle cell cancer (HCC). METHODS: Diagnosis was confirmed for 56 patients with HCC treated between 1940 and 2000, who form the basis of this study. Primary end points were relapse-free survival (RFS) and disease-specific survival (DSS). Data were analyzed with the Kaplan-Meier method and by log-rank test. RESULTS: The extent of thyroid resection did not predict outcome. Recurrence was a significant predictor of tumor-related mortality. Significant adverse predictors of RFS and DSS were degree of invasion, size >4 cm, extrathyroidal extension, and initial nodal or distant metastases. The most significant predictor of outcome was extent of invasion. Eight-year RFS values for low- and high-risk groups were 100% and 24%. Corresponding rates of 8-year DSS were 100% and 58%. CONCLUSIONS: Widely invasive HCC is an aggressive malignancy that identifies patients who are at high risk for recurrence and tumor-related death. Patients with HCC have a prognosis that is reliably predicted by degree of invasion, tumor size, extrathyroidal disease extension, and initial nodal or distant metastasis. Recurrence portends a poor outcome. High-risk patients and those with recurrence should be considered for adjuvant therapy.
BACKGROUND: The aim of this study was to define the clinical behavior and prognostic indicators of outcome in Hürthle cell cancer (HCC). METHODS: Diagnosis was confirmed for 56 patients with HCC treated between 1940 and 2000, who form the basis of this study. Primary end points were relapse-free survival (RFS) and disease-specific survival (DSS). Data were analyzed with the Kaplan-Meier method and by log-rank test. RESULTS: The extent of thyroid resection did not predict outcome. Recurrence was a significant predictor of tumor-related mortality. Significant adverse predictors of RFS and DSS were degree of invasion, size >4 cm, extrathyroidal extension, and initial nodal or distant metastases. The most significant predictor of outcome was extent of invasion. Eight-year RFS values for low- and high-risk groups were 100% and 24%. Corresponding rates of 8-year DSS were 100% and 58%. CONCLUSIONS: Widely invasive HCC is an aggressive malignancy that identifies patients who are at high risk for recurrence and tumor-related death. Patients with HCC have a prognosis that is reliably predicted by degree of invasion, tumor size, extrathyroidal disease extension, and initial nodal or distant metastasis. Recurrence portends a poor outcome. High-risk patients and those with recurrence should be considered for adjuvant therapy.
Authors: Vera Wenter; Annamirl Jellinek; Marcus Unterrainer; Freba Ahmaddy; Sebastian Lehner; Nathalie Lisa Albert; Peter Bartenstein; Thomas Knösel; Christine Spitzweg; Harun Ilhan; Andrei Todica Journal: Eur J Nucl Med Mol Imaging Date: 2019-08-13 Impact factor: 9.236
Authors: Marlon A Guerrero; Insoo Suh; Menno R Vriens; Wen T Shen; Jessica Gosnell; Electron Kebebew; Quan-Yang Duh; Orlo H Clark Journal: J Cancer Date: 2010-06-02 Impact factor: 4.207
Authors: Raj K Gopal; Kirsten Kübler; Sarah E Calvo; Paz Polak; Dimitri Livitz; Daniel Rosebrock; Peter M Sadow; Braidie Campbell; Samuel E Donovan; Salma Amin; Benjamin J Gigliotti; Zenon Grabarek; Julian M Hess; Chip Stewart; Lior Z Braunstein; Peter F Arndt; Scott Mordecai; Angela R Shih; Frances Chaves; Tiannan Zhan; Carrie C Lubitz; Jiwoong Kim; A John Iafrate; Lori Wirth; Sareh Parangi; Ignaty Leshchiner; Gilbert H Daniels; Vamsi K Mootha; Dora Dias-Santagata; Gad Getz; David G McFadden Journal: Cancer Cell Date: 2018-08-13 Impact factor: 31.743